Medications in Pregnancy and Lactation Part 1. Teratology

被引:73
作者
Buhimschi, Catalin S. [1 ]
Weiner, Carl P.
机构
[1] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA
关键词
SEROTONIN-REUPTAKE INHIBITORS; CONVERTING ENZYME-INHIBITORS; APLASIA-CUTIS-CONGENITA; IN-UTERO EXPOSURE; HUMAN BREAST-MILK; GRAVES-DISEASE; BIRTH-DEFECTS; VALPROIC ACID; MEDROXYPROGESTERONE ACETATE; INTELLECTUAL-DEVELOPMENT;
D O I
10.1097/AOG.0b013e31818d6788
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
One of the least-developed areas of clinical pharmacology and drug research is the use of medication during pregnancy and lactation. This article is the first in a two-part series designed to familiarize physicians with many aspects of the drugs they commonly prescribe for pregnant and breast-feeding women. Almost every pregnant woman is exposed to some type of medication during pregnancy. Although the majority of pregnant and breast-feeding women consume clinically indicated or over-the-counter drug preparation regularly, only few medications have specifically been tested for safety and efficacy during pregnancy. There is scant information on the effect of common pregnancy complications on drug clearance and efficacy. Often, the safety of a drug for mothers, their fetuses, and nursing infants cannot be determined until it has been widely used. Absent this crucial information, many women are either refused medically important agents or experience potentially harmful delays in receiving drug treatment Conversely, many drugs deemed "safe" are prescribed despite evidence of possible teratogenicity. Novel research and diagnostic applications evolving from the opportunities presented by the advances in genomics and proteomics are now beginning to affect clinical diagnosis, vaccine development drug discovery, and unique therapies in a modern diagnostic-therapeutic framework-part of the new scientific field of theranostics. This review critically explores a number of recently raised issues in regard to the use of several classes of medications during gestation and seeks to provide a general and concise resource on drugs commonly used during pregnancy and lactation. It also seeks to make clinicians more aware of the controversies surrounding some drugs in an effort to encourage safer prescribing practices through consultation with a maternal-fetal medicine specialist and through references and Web sites that list up-to-date information.
引用
收藏
页码:166 / 188
页数:23
相关论文
共 168 条
[51]  
Dilbaz S, 2006, J REPROD MED, V51, P87
[52]   Oral misoprostol for induction of labour at term: randomised controlled trial [J].
Dodd, JM ;
Crowther, CA ;
Robinson, JS .
BMJ-BRITISH MEDICAL JOURNAL, 2006, 332 (7540) :509-511
[53]   Exposure to mercury during the first six months via human milk and vaccines:: Modifying risk factors [J].
Dorea, Jose G. .
AMERICAN JOURNAL OF PERINATOLOGY, 2007, 24 (07) :387-400
[54]  
DUCK SC, 1981, FERTIL STERIL, V35, P230
[55]  
Duley L., 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000127
[56]  
DULEY L, 1958, COCHRANE DB SYST REV, DOI DOI 10.1009/14651858.CD002960
[57]   Low-dose, short-acting, angiotensin-converting enzyme inhibitors as rescue therapy in pregnancy [J].
Easterling, TR ;
Carr, DB ;
Davis, C ;
Diederichs, C ;
Brateng, DA ;
Schmucker, B .
OBSTETRICS AND GYNECOLOGY, 2000, 96 (06) :956-961
[58]   Treating mood disorders during pregnancy - Safety considerations [J].
Eberhard-Gran, M ;
Eskild, A ;
Opjordsmoen, S .
DRUG SAFETY, 2005, 28 (08) :695-706
[59]   Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies [J].
Einarson, TR ;
Einarson, A .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2005, 14 (12) :823-827
[60]  
Enns GM, 1999, AM J MED GENET, V86, P237, DOI 10.1002/(SICI)1096-8628(19990917)86:3<237::AID-AJMG8>3.0.CO